Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04947267
Other study ID # AAAli
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 30, 2018
Est. completion date November 19, 2019

Study information

Verified date June 2021
Source Dow University of Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As vasoconstrictors adversely affect pulpal hemodynamics, this study compared the pulpal oxygen saturation levels after employing inferior alveolar nerve block with 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) and 3% mepivacaine (3% Scandonest Plain).Two groups were made with 30 patients in each group. 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) was administered to the patients in Group A whereas 3% mepivacaine (3% Scandonest Plain) was administered to the patients in Group B. Rubber dam application, cavity preparation and composite filling was then done on the selected carious mandibular premolar. Pulpal oxygen saturation levels were recorded after administration of local anesthesia with Nellcor-550 pulse oximeter and Nellcor D-YS Multisite reusable sensor.


Description:

BACKGROUND ' Local anesthesia is the foremost requirement of an efficient operative dental procedure to be executed in a pain free and calm environment. Local anesthesia is available in two forms: with vasoconstrictor and without vasoconstrictor. As vasoconstrictors adversely affect pulpal hemodynamics, this study aims to compare the pulpal oxygen saturation levels after employing inferior alveolar nerve block with 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) and 3% mepivacaine (3% Scandonest Plain). NULL HYPOTHESIS There is no difference between the pulpal oxygen saturation levels after administering 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine. ALTERNATE HYPOTHESIS There is a difference between the pulpal oxygen saturation levels after administering 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine. METHOD Two groups were made with 30 patients in each group. 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special) was administered to the patients in Group A whereas 3% mepivacaine (3% Scandonest Plain) was administered to the patients in Group B. Rubber dam application, cavity preparation and composite filling was then done on the selected carious mandibular premolar. Pulpal oxygen saturation levels were recorded after administration of local anesthesia with the Nellcor- PM 10N pulse oximeter and Nellcor D-YS Multisite reusable sensor. STATISTICAL ANALYSIS The statistical package for social sciences version 21.0 is used for statistical analysis. Mean and standard deviation of the pulpal oxygen saturation levels for filled and unfilled teeth under the effect of 2% mepivacaine with 1:100,000 epinephrine and 3% mepivacaine were recorded. Mixed Way ANOVA will be applied to discern if there is any difference in the pulpal oxygen saturation levels within and between the two groups. Post Hoc Tuckey was applied to identify whether the paired difference is present within groups or between the two groups.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 19, 2019
Est. primary completion date September 21, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 50 Years
Eligibility Inclusion Criteria: - Medical status: healthy individuals with no current and past medical findings. - Medications: no current medications. - Both mature vital ipsilateral mandibular premolars: - Healthy premolar (ICDAS code 0) - Carious premolar (ICDAS code 4-6). - Periapical status - Healthy premolar - Periapical Index. (Code 1). - Carious premolar - Periapical Index. (Code 1). - Periodontal status - Healthy premolar - Classification of periodontal diseases and conditions (Code 0). - Carious premolar - Classification of periodontal diseases and conditions (Code 0). Exclusion Criteria: - Patients with oral and maxillofacial syndromes and anomalies. - Pregnant and nursing mothers. - Class V carious lesions (sensor of pulse oximeter was placed on intact buccal, lingual and cervical surfaces). - Teeth with extracoronal restorations. - Teeth with developmental defects and other anomalies. - Dental trauma. - Teeth with symptoms of irreversible pulpitis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
3% Mepivacaine Hydrochloride
1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
2% Mepivacaine with 1:100,000 epinephrine
1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.

Locations

Country Name City State
Pakistan Dow University of Health Sciences Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Afshan Amjad Ali

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary PULPAL OXYGEN SATURATION Pulpal oxygen saturation levels were recorded for 60 min after administration of local anesthesia using Nellcor-PM10N pulse oximeter and Nellcor D-YS Multisite reusable sensor. 60 minutes
See also
  Status Clinical Trial Phase
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Completed NCT03262857 - Effect of Lidocaine With Magnesium Sulfate on the Success of the Inferior Alveolar Nerve Block Phase 2
Withdrawn NCT03502135 - Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment Phase 4
Not yet recruiting NCT02535273 - The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia Phase 4
Not yet recruiting NCT05902780 - Can Caudal Dexmedetomidine Provide Effective Analgesia? N/A
Completed NCT04885777 - Topical Lidocaine Anesthesia for Nasopharyngeal Sampling N/A
Recruiting NCT04086394 - PECS Block in Partial Mastectomy for Postoperative Pain Control N/A
Recruiting NCT06129162 - Pain Perception Comparison of Computerized vs Conventional Injection Methods N/A
Completed NCT02922504 - Impact of Music Intervention on Pain Control In First Trimester Surgical Abortion Under Local Anesthesia N/A
Completed NCT00539084 - A Study to Assess the Safety and Efficacy of a Microneedle Device for Local Anesthesia N/A
Completed NCT03176446 - Pain and Anxiety Evaluation in Children Using Different Techniques of Local Anesthesia for Dental Treatment N/A
Completed NCT02825225 - A Prospective Randomized Trial of Two Different Prostate Biopsy Schemes N/A
Completed NCT01360749 - Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal Phase 2
Completed NCT00889642 - Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers Phase 2
Not yet recruiting NCT06395987 - Result Of Use Of Wide Awake Local Anaesthesia In Fixation Of Ankle Fractures
Active, not recruiting NCT05473819 - Effectiveness of Sodium Bicarbonate Buffered Anaesthetic Solution on Pain During Injection N/A
Completed NCT04653974 - Pain Perception of Needle-free System N/A
Completed NCT02884596 - Success of Inferior Alveolar Nerve Block in Women Taking Selective Serotonin Reuptake Inhibitors
Completed NCT02440347 - Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block Phase 4
Completed NCT02371759 - Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2 Phase 3